Open AccessIsatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis
Author(s) -
Marcelo Capra,
Thomas Martin,
Philippe Moreau,
Ross Baker,
Luděk Pour,
ChangKi Min,
Xavier Leleu,
Mohamad Mohty,
Marta Reinoso Segura,
Mehmet Turğut,
Richard LeBlanc,
MarieLaure Risse,
Laure Malinge,
Sandrine Schwab,
Meletios A. Dimopoulos
Publication year - 2021
Publication title -
haematologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.782
H-Index - 142
eISSN - 1592-8721
pISSN - 0390-6078
DOI - 10.3324/haematol.2021.279229
Subject(s) - carfilzomib , medicine , renal function , hazard ratio , dexamethasone , multiple myeloma , population , confidence interval , adverse effect , urology , gastroenterology , subgroup analysis , creatinine , oncology , lenalidomide , environmental health
Renal impairment (RI) is common in patients with multiple myeloma (MM) and new therapies that can improve renal function are needed. The Phase 3 IKEMA study (NCT03275285) investigated isatuximab (Isa) with carfilzomib and dexamethasone (Kd) vs Kd in relapsed MM. This subgroup analysis examined results from patients with RI, defined as estimated glomerular filtration rate